ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Biomarkers"

  • Abstract Number: 2498 • 2012 ACR/ARHP Annual Meeting

    Biomarkers of Mitochondrial Dysfunction Correlate with Disease Activity in SLE

    Zhi-Wei Lai1, Tiffany Telarico2, Robert Hanczko1, Adam Bartos1, Lisa Francis3, Hajra I. Tily4, Ricardo Garcia1, Maha M. Dawood5, Jianghong Yu6, Ashwini Shadakshari6, Paul E. Phillips7 and Andras Perl8, 1Medicine, SUNY, Syracuse, NY, 2Medicine, SUNY Upstate Medical University, Syracuse, NY, 3Medicine/Rheumatology, SUNY upstate medical university, Syracuse, NY, 4SUNY, NY, 5Medicine/Rheumatology, SUNY Upstate, Syracuse, NY, 6Medicine/Rheumatology, SUNY Upstate Medical University, Syracuse, NY, 7Dept of Medicine/Div of Rheum, SUNY-Upstate Medical Univ, Syracuse, NY, 8Dept of Medicine, SUNY Upstate Medical University, Syracuse, NY

    Background/Purpose: Systemic lupus erythematosus (SLE) patients’ T cells exhibit mitochondrial dysfunction, characterized by the persistent elevation of the mitochondrial transmembrane potential (Δψm) or mitochondrial hyperpolarization…
  • Abstract Number: 1707 • 2012 ACR/ARHP Annual Meeting

    The Association of Serum Biomarkers and Metabolic Syndrome with Subclinical Atherosclerosis in Systemic Lupus Erythematosus: A Controlled Analysis in Patients with No Clinical Disease Activity

    Semra Ertan-Demir1, Ahmet Yasar Cizgici2, Gaye Erten3, Bahar Artim-Esen4, Yasemin Sahinkaya4, Özlem Pehlivan4, Nilüfer Alpay-Kanitez4, Kadri Atay1, Huseyin Oflaz2, Gunnur Deniz3 and Murat Inanc4, 1Department of Internal Medicine, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, 2Cardiology Department, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, 3Department of Immunology, Istanbul University, Institute of Experimental Medicine (DETAE), Istanbul, Turkey, 4Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey

    Background/Purpose: Patients with systemic lupus erythematosus (SLE) have an increased risk of developing atherosclerotic cardiovascular disease (CVD). In addition to traditional CVD risk factors or…
  • Abstract Number: 1078 • 2012 ACR/ARHP Annual Meeting

    Prolactin Is Increased in Responders to Anti-TNFá Treatment and the Role of the Prolactin Receptor in Rheumatoid Arthritis

    Man Wai Tang1, Danielle Marie Gerlag2, Veronica Codullo3, Elsa Vieira-Sousa4, Anne Q. Reuwer5, Marcel T. Twickler5, Robert B. M. Landewé6 and Paul Peter Tak7, 1Division of Clinical Immunology and Rheumatology & Department of Experimental Immunology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, 2Clinical Immunology and Rheumatology, Academic Medical Center, Amsterdam, Netherlands, 3Rheumatology, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, 4Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, 5Vascular Medicine, Academic Medical Center/University of Amsterdam, Amsterddam, Netherlands, 6Academic Medical Center/University of Amsterdam & Atrium Medical Center, Amsterdam, Netherlands, 7Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands

    Background/Purpose: Rheumatoid arthritis (RA) is the most common rheumatic disease which mainly affects women. In the last decade, it is known that prolactin (PRL) is…
  • Abstract Number: 680 • 2012 ACR/ARHP Annual Meeting

    Plasma Level of Galectin-3 Binding Protein Reflects Type I Interferon Activity and Is Highly Increased in Patients with Systemic Lupus Erythematosus

    Christoffer T. Nielsen1, Ole Østergaard2, Line V. Iversen3, Christian Lood4, Anders A. Bengtsson4, Anne Voss5, Søren Jacobsen6 and Niels H. H. Heegaard3, 1Department of Clinical Biochemistry, Immunology & Genetics, Statens Serum Institut, Copenhagen S, Denmark, 2Department of Clinical Biochemistry, Immunology & Genetics, Statens Serum Institute, Copenhagen S, Denmark, 3Department of Clinical Biochemistry, Immunology & Genetics, Statens Serum Institut, Copenhagen, Denmark, 4Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund, Sweden, 5Dept of Rheumatology, Odense University Hospital, Odense C, Denmark, 6Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

    Background/Purpose: Ongoing production of type I interferons (IFN) is a key element in the pathogenesis of systemic lupus erythematosus (SLE). Type I IFNs trigger the…
  • Abstract Number: 256 • 2012 ACR/ARHP Annual Meeting

    Strontium Ranelate Decreases the Level of Urinary CTX-II in Patients with Knee Osteoarthritis

    Julien Collette1, Olivier Bruyere2 and Jean-Yves Reginster3, 1University of Liege, Labo Ria Chu Sart Tilman, Liege, Belgium, 2Public Health/Epidemiology, University of Liege, Liege, Belgium, 3Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium

    Background/Purpose: Knee osteoarthritis is a chronic disease affecting the global joint and characterized by cartilage degradation as well as subchondral bone remodelling. Effects of strontium…
  • Abstract Number: 2500 • 2012 ACR/ARHP Annual Meeting

    Podocyte Injury in Membranous and Proliferative Lupus Nephritis: Distinct Underlying Mechanisms?

    Gabriela M. Rezende1, Vilma S. T. Viana1, Denise M. Malheiros2, Elaine P. Leon3, Eduardo F. Borba1, Neila AS Silva2, Irene L. Noronha4, Cleonice Silva4 and Eloisa Bonfá5, 1Internal Medicine, Division of Rheumatology - Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 2Division of AnatomoPathology - Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 3Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 4Internal Medicine, Division of Nephrology - Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 5Division of Rheumatology, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil

    Background/Purpose: Lupus nephritis (LN) is a major cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE) with proteinuria being the predominant common…
  • Abstract Number: 1623 • 2012 ACR/ARHP Annual Meeting

    Serum Biomarkers Signature Identifies Patients with Overt B-Cell Non-Hodgkin Lymphoma Associated with Mixed Cryoglobulinemia in Chronic HCV Infection

    Benjamin Terrier1, Wahiba Chaara2, Guillaume Geri3, David Saadoun4, Michelle Rosenzwajg Sr.5, Damien Sene Sr.6, Adrien Six2, David Klatzmann Sr.5 and Patrice Cacoub Sr.7, 1Internal Medicine, Cochin University Hospital, Paris, France, 2Laboratory I3 “Immunology, Immunopathology, Immunotherapy”, UMR CNRS 7211, INSERM U959, Groupe Hospitalier Pitié-Salpetrière, Paris, France, 3Intensive Care Unit, Cochin Hospital, Paris, France, 4Groupe Hospitalier Pitié Salpétrière, Service de Médecine Interne, DHU i2B, Paris, France, 5Laboratory I3 “Immunology, Immunopathology, Immunotherapy”, UMR CNRS 7211, INSERM U959, Paris, France, 6Department of Internal Medicine; 5 P3S post-genomic plateform, Groupe Hospitalier Pitié-Salpétrière, Université Pierre et Marie Curie, Paris, France, 7Department of Internal Medicine 2., CHU Pitié-Salpêtrière, Paris, France

    Background/Purpose: Hepatitis C virus (HCV) is associated with B-cell disorders, including mixed cryoglobulinemia (MC) and B-cell non-Hodgkin lymphoma (B-NHL). Early diagnosis of B-NHL in HCV-infected…
  • Abstract Number: 1050 • 2012 ACR/ARHP Annual Meeting

    Assessment of Validity of Magnetic Resonance Imaging Measures of Joint Inflammation and Damage in Rheumatoid Arthritis Wrist/Hand – a Systematic Literature Review

    TG Woodworth1, O. Morgacheva2, OM Troum3, OL Pimienta4, P. Maranian5, V.K. Ranganath5 and Daniel Furst5, 1Medicine, Division of Rheumatology, David Geffen School of Medicine, University of California, Los Angeles, CA, 2Medicine/Division of Rheumatology, David Geffen School of Medicine, UCLA, Los Angeles, CA, 3Medicine, USC Keck School of Medicine, Santa Monica, CA, 4Keck School of Medicine, University of Southern California, Los Angeles, CA, 5Medicine, Division of Rheumatology, David Geffen School of Medicine, UCLA, Los Angeles, CA

    Background/Purpose: Limitation of x-ray joint damage is a key indicator of therapeutic efficacy in rheumatoid arthritis (RA). Although magnetic resonance imaging (MRI) is increasingly used…
  • Abstract Number: 686 • 2012 ACR/ARHP Annual Meeting

    Cell-Type Specific Type I Interferon Signatures in Autologous Stem Cell Transplanted Lupus Patients: Different Molecular Behavior Between CD4+ T Cells and Monocytes

    Chieko Kyogoku1, Joachim R. Grün1, Tobias Alexander2, Robert Biesen3, Falk Hiepe4, Thomas Häupl3, Andreas Radbruch1 and Andreas Grützkau1, 1German Rheumatism Research Centre Berlin (DRFZ), an institute of the Leibniz Association, Berlin, Germany, 2Department of Rheumatology and Clinical Immunology, Charité – University Hospital, Berlin, Germany, 3department of Rheumatology and Clinical Immunology, Charité University Hospital Berlin, Berlin, Germany, 4Med. Klinik m. Sp. Rheumatologie und klin. Immunologie, Charité University Hospital Berlin, Berlin, Germany

    Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease that affects multiple organs, whose pathology is mainly caused by the augmented interferon (IFN)…
  • Abstract Number: 207 • 2012 ACR/ARHP Annual Meeting

    Interferon-Driven Chemokines Are Associated with Changes in Disease Activity Among Rituximab-Treated Refractory Myositis  Patients with Pulmonary Involvement – the RIM Study

    Cynthia S. Crowson1, Ann M. Reed2, Molly Hein3, Abigail B. Green1, Consuelo Lopez de Padilla4, Rohit Aggarwal5, Dana P. Ascherman6, Marc C. Levesque7 and Chester V. Oddis8, 1Department of Health Sciences Research, Mayo Clinic, Rochester, MN, 2Rheumatology, Mayo Clinic, Rochester, MN, 3Mayo Clinic, Rochester, MN, 4Rheumatology/Immunology Research, Mayo Clinic, Rochester, MN, 5Medicine, University of Pittsburgh, Pittsburgh, PA, 6Medicine/Rheumatology, University of Miami, Miami, FL, 7Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 8Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: The Rituximab in Myositis (RIM) Study provides a unique resource for biomarker investigation of homogeneously treated refractory adult and juvenile myositis patients. Building on…
  • « Previous Page
  • 1
  • …
  • 94
  • 95
  • 96
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology